For example, a type I interferon, IFNA1, presenting a significantly higher response in severe COVID-19 patients, surged during the early phase of symptom onset and gradually declined, whereas IFNL3, a type III interferon, which was also significantly elevated in the severe group compared with the moderate group, gradually increased in severe patients during disease progression (Figure 2B). Here, IFNL3 is linked to COVID-19.